This page includes Regulatory news filings supplied by issuers listed on the BSX. Please note the BSX is not responsible for the content, accuracy or completeness of announcements filed by issuers and disclaims all liability for any loss arising from reliance on information contained within issuer announcements.

ImuMed Issues Further Statement

23 April 2001

Hamilton, Bermuda: 23 April, 2001- The Directors of ImuMed International Ltd. have today issued the following statement subsequent to the suspension of the Company's shares on the Bermuda Stock Exchange (BSX).

"ImuMed International Ltd. is currently in negotiations with various sources in respect of financing opportunities which may be available to the Company. Discussions are also in progress with creditors to ensure the viability of the Company's activities in the longer term. In these circumstances, the Directors have requested that the present suspension should be extended pending the potential recovery of ImuMed Deutschland GmbH (Antitoxin), together with its subsidiaries, Antitoxin Dr. Helmbold GmbH, Institut fur Immuntherapie Antitoxin Verwaltungs GmbH and Institut fur Immuntherapie Antitoxin GmbH & Co. KG, from bankruptcy proceedings in Germany."

The BSX has granted the Company's request for the suspension of its securities to be extended pending further developments.